Elisa Bergaggio

Ph.D. researching CAR-T in neuroblastoma at @BostonChildrens in @chiarlelab. @AICF_nyc Fellow.

[Society for Immunotherapy of Cancer @sitcancer]

Congratulations to Dr. Elisa Bergaggio of @BostonChildrens, recipient of the 2024-Bristol Myers Squibb (@bmsnews) Postdoctoral Cancer Immunotherapy Translational Fellowship, a 2-year, $200K SITC Fellowship! https://t.co/8mHMS4uSiJ

[Dr. Patrick Hwu @PatrickHwuMD]

#ScienceSaturday How can we target #neuroblastoma, the most common extracranial solid tumor in children, with CAR-T cells? @ElisaBergaggio, @robertochiarle, et al have recently utilized CAR-T against the ALK receptor in preclinical models of neuroblastoma. Importantly, ALK inhibitors enhanced the activity of the ALK-specific CAR-T, partially by increasing the surface expression of the ALK target. This is a promising strategy against neuroblastoma, which accounts for 12-15% of #cancer deaths in children.

Here’s a link to the full article- https://t.co/nyR6EOCyT9

[Marco Ruella @MarcoRuella]

My commentary on a cool paper from @chiarlelab combining ALK inhibitors and ALK-CART... I also took the opportunity to review the most recent successes of #CART in solid cancers! @PennMedicine @CR_AACR
https://t.co/hPiTVGAD9F

[ACIR @ACIR_org]

The anaplastic lymphoma kinase (ALK) receptor is an oncogenic driver specifically expressed by neuroblastoma [...] https://t.co/mKknfdULpy  @ElisaBergaggio  @robertochiarle

[Chiarle lab @chiarlelab]

Check out our paper on @ScienceTM that deciphers how to overcome ALK TKIs resistance in ALK+ lymphoma by targeting the CCR7-PI3Kgamma pathway. Congrats to all the talented scientists that helped the work! It's on the cover! @BostonChildrens @unito
https://t.co/ICoZUSftVW

[Elisa Bergaggio @ElisaBergaggio]

Congratulations to my amazing friend @MMoscvin for her match in IM at @StanfordMed! You really deserved this achievement. I'm so proud of you and excited about your bright future!

[Maria Moscvin @MMoscvin]

I am so excited for the future✨